Actively Recruiting
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Led by Brigham and Women's Hospital · Updated on 2025-12-10
30
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
C
Charles A. King Trust Postdoctoral Fellowship Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Although weight loss with calorie restriction and increased physical activity improve these complications, many people fail these lifestyle interventions. Therefore, pharmacologic agents have been used for weight management in addition to lifestyle interventions. In the past few years, one of the widely used pharmacologic agents for weight management is Glucagon-like peptide 1 receptor agonists (GLP1 RAs). Overall, this class of medications improves both metabolic and cardiovascular profiles while causing weight loss, but their effects can vary between individuals. Therefore, it is essential to understand who will respond best to this therapy. Based on previous research on the interaction between a cell membrane molecule, caveolin-1, and glucagon-like peptide 1 receptor, we hypothesize that genetic variations in the caveolin-1 gene explain the variable cardiometabolic responses.
CONDITIONS
Official Title
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Body mass index (BMI) of 30.0 kg/m2 or greater, or 27.0 kg/m2 or greater with at least one weight-related condition such as hypertension, prediabetes, dyslipidemia, or obstructive sleep apnea
- Normal screening laboratory test results
- Systolic blood pressure less than 160 mmHg and diastolic blood pressure less than 95 mmHg measured during screening
- Use of anti-hypertensive medications allowed except for mineralocorticoid receptor antagonists
You will not qualify if you...
- Diagnosis of diabetes mellitus
- Use of glucose-lowering or anti-obesity medications within 90 days before screening
- Use of GLP-1 receptor agonists within 180 days before screening
- Current treatment with beta-blockers or steroids
- Pregnancy
- Personal history of pancreatitis
- Personal history of gallstones (cholelithiasis)
- Previous surgical treatment for obesity
- Personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
- Medical illnesses other than hypertension, prediabetes, obstructive sleep apnea, or dyslipidemia
- Alcohol consumption greater than 12 ounces per week
- Use of tobacco or recreational drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
E
Ezgi Caliskan Guzelce, M.D.
CONTACT
G
Gail K.Adler, M.D.,PhD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here